Korean biopharma making biosimilar copies of blockbuster biologic drugs and developing new antibody therapies, sold via its own global sales force.
Korean biopharma making biosimilar copies of blockbuster biologic drugs and developing new antibody therapies, sold via its own global sales force.
Manufactures biosimilars, near copies of expensive biotech drugs that have lost patent protection, in its own plants and sells them through its own overseas sales arm rather than through partners, which keeps a larger share of the income. Founder Seo Jung-jin controls it through Celltrion Holdings.
In one line: Korea's biosimilar-focused biotech, akin to a smaller Sandoz..
Moat: narrow (regulatory licence, scale, brand). Early mover with FDA/EMA-approved biosimilars and its own direct US/EU sales network.
Headquarters: Incheon, South Korea · Founded: 2002 · Employees: 3,153
Size Celltrion (068270.KS) is a South Korea Health Care company (Biotechnology) with a market value of $34.9B, the 9th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩207,500 on 18 Nov 2026.
Performance Over six months the shares gained 11.7%, against +35.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 39.7% over the last twelve months (peer median +13.9%); the operating margin is 32.5% (peer median 22.9%).
Valuation It trades at 33.9× forward earnings against a peer median of 23.9× (6th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.0 points above its cost of capital (5.5% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩5.44T | ₩4.16T | ₩3.56T | ₩2.18T | ₩2.28T |
| Revenue growth | — | +17% | +63% | -5% | — |
| Gross profit | ₩3.28T | ₩2.40T | ₩1.51T | ₩1.01T | ₩992B |
| EBITDA | ₩2.07T | ₩1.45T | ₩910B | ₩897B | ₩822B |
| Net income | ₩1.32T | ₩1.03T | ₩423B | ₩536B | ₩530B |
| Free cash flow | ₩727B | ₩478B | ₩727B | ₩303B | -₩120B |
| Capital expenditure | ₩514B | ₩332B | ₩334B | ₩358B | ₩312B |
| Total debt | ₩3.80T | ₩3.73T | ₩2.19T | ₩1.89T | ₩792B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Celltrion 068270.KS | $34.9B | +12% | +40% | 32% | 33.9× | 10.6% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 18.3× | 1.6% |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 068270.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.1% | +0.9% | 9th highest of 21 |
| 6-month return | +11.7% | +35.0% | 6th lowest of 21 |
| Distance from 52-week high | -13.2% | -14.3% | 10th highest of 21 |
| Revenue growth (TTM) | +39.7% | +13.9% | 5th highest of 21 |
| Operating margin | 32.5% | 22.9% | 4th highest of 21 |
| Forward P/E | 33.9× | 23.9× | 6th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 10.6% | 8.2% | 8th most demanding of 16 |
| Growth delivered (Del g) | +17.6% | +12.0% | 7th highest of 16 |
| Hurdle (Req g minus delivered) | -7.0 pp | -7.9 pp | 8th most demanding of 16 |
| ROIC minus cost of capital | +1.0 pp | +0.6 pp | 11th highest of 21 |
| EV / EBITDA | 23.9× | 16.0× | 5th most expensive of 15 |
| Net debt / EBITDA | 1.2× | 0.8× | 8th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Celltrion 068270.KS | South Korea | $34.9B | +12% | +40% | 32% | 33.9× | 10.6% | +17.6% |
| Genmab A/S GMAB.CO | Denmark | $30.8B | +103% | +15% | 31% | 40.9× | 11.6% | +19.5% |
| Natera NTRA | United States | $42.0B | +41% | +37% | -9% | n/a | n/a | n/a |
| Iqvia IQV | United States | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% | +7.5% |
| Samsung Biologics 207940.KS | South Korea | $48.7B | -6% | -20% | 43% | 34.4× | 7.0% | +31.4% |
| United Therapeutics UTHR | United States | $24.6B | +2% | +2% | 44% | 23.9× | 0.3% | +16.5% |
| Wuxi Bio 2269.HK | Hong Kong | $23.1B | +35% | +22% | 32% | 26.5× | 20.8% | +30.2% |
| Lonza LONN.SW | Switzerland | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% | +7.7% |
| BioNTech SE Sponsored ADR BNTX | United States | $20.6B | -8% | -21% | -61% | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | United States | $59.1B | +17% | +71% | 29% | 29.0× | 11.7% | +151.4% |
| CSL CSL.AX | Australia | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% | +11.0% |
| Neurocrine Biosciences NBIX | United States | $16.5B | +5% | +38% | 25% | 18.0× | -1.5% | +22.3% |
| Moderna MRNA | United States | $79.6B | +309% | +13% | -116% | n/a | n/a | n/a |
| BridgeBio Pharma BBIO | United States | $15.2B | +14% | +167% | -37% | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% | +7.6% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% | +0.1% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% | +12.0% |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% | +5.5% |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% | +39.2% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | n/a | n/a | n/a |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% | +2.3% |